Coral Genomics
Improves drug development and deployment by utilizing genomic data from patients to determine how they will respond to a drug before they get treated.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
$2.0m | Grant | ||
| Total Funding | 000k | ||
Related Content
Coral Genomics operates in the precision medicine market, focusing on integrating genetic testing with molecular, functional, and clinical data to provide personalized healthcare solutions. The company serves healthcare providers, large health systems, and research institutions. Coral's business model revolves around offering clinical sequencing products, including rapid whole exome sequencing, which can be flexibly deployed across various healthcare settings. The company generates revenue through the sale of these sequencing products and associated services, which include the creation of interpretable patient reports and universal risk scores. Coral's solutions aim to improve the clinical utility of genetic testing, enhance healthcare delivery efficiency, and maximize patient privacy. The company also emphasizes education, activism, and action to address systemic racism and increase diversity in the healthcare workforce.
Keywords: precision medicine, genetic testing, molecular data, functional data, clinical data, personalized healthcare, whole exome sequencing, patient privacy, healthcare efficiency, diversity.